Eloxx Pharmaceuticals Inc To Host Investor and Analyst Call on Alport Syndrome Transcript
Ladies and gentlemen, thank you for standing by. And welcome to the Eloxx Pharmaceuticals webcast to discuss the unmet need in Alport syndrome and additional clinical data results from the topline ELX-02 Phase 2 clinical trial.
(Operator Instructions) I would now like to turn the conference over to your first speaker today, Sumit Aggarwal, Eloxx's President and Chief Executive Officer. Sumit, you may begin.
Thank you. Welcome, everyone, listening to the call today. We're excited about sharing the Alport syndrome overview and our results in ELX-02. This is a very exciting time for Eloxx as we plan our pivotal study in Alport.
On the next slide, you see that we're going to be making some forward-looking statements. Please refer to our SEC documents for detailed risk factors.
Now, turning over to the agenda on the next slide, we're really excited to have Professors Rachel Lennon and Detlef BĂ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsâ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |